



Therapix Biosciences to examine the development of a cannabinoid-based drug for treating Tourette's syndrome

In the last several decades, no new drug was developed or launched for treating Tourette's syndrome. Tourette's syndrome is a neurological disorder characterized by involuntary movements and vocalizations.

August 4, 2015

Further to Therapix Biosciences' strategic plan determined at the beginning of 2014, the Company announced to investors this morning that the Company's Board of Directors has decided to focus its business strategy on the field of cannabinoid-based treatment. Therapix's Board of Directors approved the examination of the advancement of a program for developing a cannabinoid-based treatment for Tourette's syndrome, by itself or in collaboration with third parties, while utilizing its entourage technology.

The entourage technology is based on the integration of cannabinoid substances in existing drugs, with a view to improve treatment. To the best of Therapix's knowledge and estimation, in the last several decades, no new drug was developed or launched for treating Tourette's syndrome, and such clinical program may enable a regulatory track under an orphan drug designation.

Choosing Tourette's syndrome under an orphan drug program derives from the Company's decision to engage in the development of cannabinoid-based drugs under fast-track regulatory programs compared with the standard course of drug development (an orphan drug regulatory track may allow an accelerated regulatory process).

Tourette's syndrome is a neurological disorder characterized by involuntary movements and vocalizations, involuntary muscular contractions (tics) and extreme stigmatization. Data presented in a number of studies attest to the positive advantages of treating involuntary contractions by using cannabinoid substances.